ANSAID TABLETS 100 MG
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
12-10-2016
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
FLURBIPROFEN
Available from:
PFIZER CANADA ULC
ATC code:
M01AE09
INN (International Name):
FLURBIPROFEN
Dosage:
100MG
Pharmaceutical form:
TABLET
Composition:
FLURBIPROFEN 100MG
Administration route:
ORAL
Units in package:
100
Prescription type:
Prescription
Therapeutic area:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Product summary:
Active ingredient group (AIG) number: 0115998001; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2013-07-25
Summary of Product characteristics
_ _
PRODUCT MONOGRAPH
ANSAID*
Flurbiprofen tablets USP
50 mg and 100 mg Tablets
Nonsteroidal anti-inflammatory drug (NSAID)
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
www.pfizer.ca
DATE OF REVISION:
FEBRUARY 3, 2010
SUBMISSION CONTROL NO: 133863
*
TM Pharmacia & Upjohn Company LLC
Pfizer Canada Inc, Licensee
©
Pfizer Canada Inc 2010
_ _
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL
INFORMATION......................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II:
SCIENTIFIC
INFORMATION..............................................................................25
PHARMACEUTICAL
INFORMATION..........................................................................25
CLINICAL
TRIALS..........................................................................................................25
DETAILED
PHARMACOLOGY...
Read the complete document
